Abstract
As millions of glaucoma patients lose sight, it is evident that there is a need to develop neuroprotective therapies that can be used to prevent retinal ganglion cell (RGC) death. Advances in understanding of the glaucoma make it evident that perfusion abnormalities are a key factor in the pathogenesis of glaucomatous neuropathy. Based on findings in similar diseases, we hypothesize that …
